CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, similar to K562 and murine LSK, we also observed reduced cell viability and increased apoptosis of CD34+ cells from IM-persistent CML patient samples treated with both IM and shikonin (Fig. S6H–I).